CELZ Receives FDA Clearance to Expand ADAPT Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Expansion: Creative Medical Technology Holdings, Inc. (CELZ) has received FDA clearance to expand its ADAPT clinical trial evaluating Olastrocel (CELZ-201) for chronic lower back pain, marking a significant step toward Phase 3 planning.
- Patient Recruitment Plan: Under the amended protocol, the company will enroll an additional 15 patients taking less than 90 mg of morphine equivalents per day to further assess safety and efficacy in ongoing opioid users, with over 85% of the new cohort already enrolled.
- Positive Interim Data: Following the completion of enrollment in the original ADAPT population, interim data at 180 days showed statistically significant improvements in pain and functional disability, with an independent Data Safety Monitoring Board reporting no significant adverse events and recommending continued program advancement.
- Market Positioning Strategy: CELZ aims to position Olastrocel as a scalable allogeneic regenerative therapy in a market still dominated by opioids, injections, and invasive surgical procedures, with the CEO emphasizing the use of its AI-driven monitoring platform to build a robust real-world data package.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CELZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CELZ
About CELZ
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Creative Medical Technology Holdings Shares Surge 78% Following Warrant Exercise Agreement
- Financing Agreement Reached: Creative Medical Technology announced the exercise of existing warrants, expected to generate approximately $4.5 million in gross proceeds, with shares surging 78% during trading, reflecting strong market confidence in the company's future.
- Warrant Details: The financing includes the immediate exercise of 2,790,340 shares of warrants at an exercise price of $1.60 per share, with investors also agreeing to purchase 5,580,680 shares at the same price, enhancing the company's capital base.
- Clear Use of Proceeds: The company stated that net proceeds will be used for working capital and general corporate purposes, supporting the advancement of its regenerative medicine and immunotherapy pipeline, indicating a strong focus on future technological development.
- Stock Price Fluctuation: Over the past year, CELZ shares have fluctuated between $0.79 and $6.25, closing at $1.45, and although down 8.28% in after-hours trading, the overall trend still indicates positive investor sentiment.
See More
Creative Medical Technology Holdings Announces Stock Warrant Exercise
- Financing Scale: Creative Medical Technology Holdings has entered into agreements for the immediate exercise of warrants, expected to raise approximately $4.5 million, enhancing the company's liquidity to support operations and growth.
- New Warrant Issuance: The company will issue new unregistered warrants allowing the purchase of 5,580,680 shares at an exercise price of $1.60 per share, effective upon shareholder approval, further strengthening its capital structure.
- Registration Statement Filing: The company has committed to filing a registration statement with the SEC to cover the resale of common stock upon exercise of the new warrants, ensuring compliance and paving the way for future financing.
- Market Impact: This transaction is expected to close on June 30, 2026, marking a significant step in the company's ongoing development in the biotechnology sector, particularly in strategic investments in regenerative medicine and immunotherapy.
See More
Creative Medical Technology Announces Public Offering of 3.05 Million Shares
- Public Offering Announcement: Creative Medical Technology has announced a public offering of up to 3.05 million shares of common stock at an assumed price of $1.97 per share, including warrants for an additional 6.09 million shares, aimed at raising capital for future growth despite a 35% decline in stock value this year.
- GD Culture Reverse Split: GD Culture Group is set to implement a 1-for-250 reverse stock split on June 29, reducing its outstanding shares from approximately 1.04 billion to about 4.16 million, yet the stock has plummeted over 99% this year, indicating a severe loss of market confidence.
- Baiya International Stake Sale: Baiya International Group sold its entire stake in Juxing Investment Group (Hong Kong) to Shengshi International for $2 million, but BIYA stock remains weak, currently trading at an intraday low of $0.32, reflecting ongoing market struggles.
- Poor Market Performance: Shares of Creative Medical Technology, Baiya International, and GD Culture hit their 52-week lows on Friday, with CELZ down 33%, BIYA down 14%, and GDC down over 23%, highlighting a significant decline in investor confidence across these companies.
See More
CELZ Receives FDA Clearance to Expand ADAPT Clinical Trial
- Clinical Trial Expansion: Creative Medical Technology Holdings, Inc. (CELZ) has received FDA clearance to expand its ADAPT clinical trial evaluating Olastrocel (CELZ-201) for chronic lower back pain, marking a significant step toward Phase 3 planning.
- Patient Recruitment Plan: Under the amended protocol, the company will enroll an additional 15 patients taking less than 90 mg of morphine equivalents per day to further assess safety and efficacy in ongoing opioid users, with over 85% of the new cohort already enrolled.
- Positive Interim Data: Following the completion of enrollment in the original ADAPT population, interim data at 180 days showed statistically significant improvements in pain and functional disability, with an independent Data Safety Monitoring Board reporting no significant adverse events and recommending continued program advancement.
- Market Positioning Strategy: CELZ aims to position Olastrocel as a scalable allogeneic regenerative therapy in a market still dominated by opioids, injections, and invasive surgical procedures, with the CEO emphasizing the use of its AI-driven monitoring platform to build a robust real-world data package.
See More
Creative Medical Receives FDA Clearance for Expanded Clinical Trial
- Clinical Trial Expansion: Creative Medical's ADAPT clinical trial has received FDA clearance to enroll an additional 15 patients, focusing on assessing the safety and efficacy of CELZ-201 in chronic lower back pain patients, particularly those using less than 90 mg morphine equivalents.
- Rapid Enrollment Progress: The new cohort has already surpassed 85% enrollment, with expectations to complete by the end of summer 2026, providing the company with a richer dataset to support future regulatory planning and Phase 3 discussions.
- AI Monitoring System Implementation: The expansion cohort will leverage the company's newly implemented AI-driven pain medication monitoring system to capture real-time patient-reported outcomes and analgesic use patterns, enhancing data accuracy and timeliness, thereby improving trial quality.
- Market Potential and Strategic Significance: Creative Medical is committed to developing non-opioid treatment options to address the chronic lower back pain and opioid overdose crisis in the U.S., with the success of Olastrocel potentially offering new therapeutic choices for patients while creating significant value for shareholders.
See More
CELZ Biodefense Platform Approved for Expansion
- Launch of Project PHOENIX: Creative Medical announced the regulatory approval of its CELZ Biodefense platform, designed to support at least 1,000 veterans through AI-enabled mobile app data collection, significantly enhancing responsiveness to toxic exposure.
- Data Collection Innovation: The platform employs a decentralized model allowing veterans to participate via a mobile app, capturing exposure history and health information, which is expected to greatly improve data accessibility and quality, thereby driving future therapeutic development.
- Multi-Omics Integration: The project will integrate multi-omics data, including genomic, transcriptomic, and proteomic information, to identify biomarkers and disease pathways associated with toxic exposure, providing crucial support for precision therapies and holding significant strategic implications.
- Capital-Efficient Execution: The company plans to leverage existing infrastructure and intellectual property for project implementation, with no additional fundraising anticipated, and this capital-efficient structure will help advance the Biodefense initiative while maintaining shareholder value.
See More
Creative Medical Technology Holdings Shares Surge 78% Following Warrant Exercise Agreement
- Financing Agreement Reached: Creative Medical Technology announced the exercise of existing warrants, expected to generate approximately $4.5 million in gross proceeds, with shares surging 78% during trading, reflecting strong market confidence in the company's future.
- Warrant Details: The financing includes the immediate exercise of 2,790,340 shares of warrants at an exercise price of $1.60 per share, with investors also agreeing to purchase 5,580,680 shares at the same price, enhancing the company's capital base.
- Clear Use of Proceeds: The company stated that net proceeds will be used for working capital and general corporate purposes, supporting the advancement of its regenerative medicine and immunotherapy pipeline, indicating a strong focus on future technological development.
- Stock Price Fluctuation: Over the past year, CELZ shares have fluctuated between $0.79 and $6.25, closing at $1.45, and although down 8.28% in after-hours trading, the overall trend still indicates positive investor sentiment.
See More
Creative Medical Technology Holdings Announces Stock Warrant Exercise
- Financing Scale: Creative Medical Technology Holdings has entered into agreements for the immediate exercise of warrants, expected to raise approximately $4.5 million, enhancing the company's liquidity to support operations and growth.
- New Warrant Issuance: The company will issue new unregistered warrants allowing the purchase of 5,580,680 shares at an exercise price of $1.60 per share, effective upon shareholder approval, further strengthening its capital structure.
- Registration Statement Filing: The company has committed to filing a registration statement with the SEC to cover the resale of common stock upon exercise of the new warrants, ensuring compliance and paving the way for future financing.
- Market Impact: This transaction is expected to close on June 30, 2026, marking a significant step in the company's ongoing development in the biotechnology sector, particularly in strategic investments in regenerative medicine and immunotherapy.
See More
Creative Medical Technology Announces Public Offering of 3.05 Million Shares
- Public Offering Announcement: Creative Medical Technology has announced a public offering of up to 3.05 million shares of common stock at an assumed price of $1.97 per share, including warrants for an additional 6.09 million shares, aimed at raising capital for future growth despite a 35% decline in stock value this year.
- GD Culture Reverse Split: GD Culture Group is set to implement a 1-for-250 reverse stock split on June 29, reducing its outstanding shares from approximately 1.04 billion to about 4.16 million, yet the stock has plummeted over 99% this year, indicating a severe loss of market confidence.
- Baiya International Stake Sale: Baiya International Group sold its entire stake in Juxing Investment Group (Hong Kong) to Shengshi International for $2 million, but BIYA stock remains weak, currently trading at an intraday low of $0.32, reflecting ongoing market struggles.
- Poor Market Performance: Shares of Creative Medical Technology, Baiya International, and GD Culture hit their 52-week lows on Friday, with CELZ down 33%, BIYA down 14%, and GDC down over 23%, highlighting a significant decline in investor confidence across these companies.
See More
CELZ Receives FDA Clearance to Expand ADAPT Clinical Trial
- Clinical Trial Expansion: Creative Medical Technology Holdings, Inc. (CELZ) has received FDA clearance to expand its ADAPT clinical trial evaluating Olastrocel (CELZ-201) for chronic lower back pain, marking a significant step toward Phase 3 planning.
- Patient Recruitment Plan: Under the amended protocol, the company will enroll an additional 15 patients taking less than 90 mg of morphine equivalents per day to further assess safety and efficacy in ongoing opioid users, with over 85% of the new cohort already enrolled.
- Positive Interim Data: Following the completion of enrollment in the original ADAPT population, interim data at 180 days showed statistically significant improvements in pain and functional disability, with an independent Data Safety Monitoring Board reporting no significant adverse events and recommending continued program advancement.
- Market Positioning Strategy: CELZ aims to position Olastrocel as a scalable allogeneic regenerative therapy in a market still dominated by opioids, injections, and invasive surgical procedures, with the CEO emphasizing the use of its AI-driven monitoring platform to build a robust real-world data package.
See More
Creative Medical Receives FDA Clearance for Expanded Clinical Trial
- Clinical Trial Expansion: Creative Medical's ADAPT clinical trial has received FDA clearance to enroll an additional 15 patients, focusing on assessing the safety and efficacy of CELZ-201 in chronic lower back pain patients, particularly those using less than 90 mg morphine equivalents.
- Rapid Enrollment Progress: The new cohort has already surpassed 85% enrollment, with expectations to complete by the end of summer 2026, providing the company with a richer dataset to support future regulatory planning and Phase 3 discussions.
- AI Monitoring System Implementation: The expansion cohort will leverage the company's newly implemented AI-driven pain medication monitoring system to capture real-time patient-reported outcomes and analgesic use patterns, enhancing data accuracy and timeliness, thereby improving trial quality.
- Market Potential and Strategic Significance: Creative Medical is committed to developing non-opioid treatment options to address the chronic lower back pain and opioid overdose crisis in the U.S., with the success of Olastrocel potentially offering new therapeutic choices for patients while creating significant value for shareholders.
See More
CELZ Biodefense Platform Approved for Expansion
- Launch of Project PHOENIX: Creative Medical announced the regulatory approval of its CELZ Biodefense platform, designed to support at least 1,000 veterans through AI-enabled mobile app data collection, significantly enhancing responsiveness to toxic exposure.
- Data Collection Innovation: The platform employs a decentralized model allowing veterans to participate via a mobile app, capturing exposure history and health information, which is expected to greatly improve data accessibility and quality, thereby driving future therapeutic development.
- Multi-Omics Integration: The project will integrate multi-omics data, including genomic, transcriptomic, and proteomic information, to identify biomarkers and disease pathways associated with toxic exposure, providing crucial support for precision therapies and holding significant strategic implications.
- Capital-Efficient Execution: The company plans to leverage existing infrastructure and intellectual property for project implementation, with no additional fundraising anticipated, and this capital-efficient structure will help advance the Biodefense initiative while maintaining shareholder value.
See More
